INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Cislini Jeff sold RVMD

SVP & General Counsel · Revolution Medicines, Inc. · Common Stock

Side
SELL
Value
$159K
Shares
765
Price
$207.32
Executed
Sep 25, 2026
Disclosed
Sep 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 25 executedSep 29, 2026 disclosed

RVMD · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
19/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+4 / 25

    $159K reported value · 1.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering+15 / 15

    4 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RVMD

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M$353K
    6,000 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,000 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    19
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$244K
    1,199 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    19
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$203K
    1,000 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    22
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$325K
    1,609 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    22
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$442K
    2,200 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    19
    SB
    Sandler Alan B.Chief Development Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$62K
    301 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MA
    Mancini AnthonySee Remarks
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$117K
    587 sh
    		Sep 24, 2026Sep 28, 2026
    traded Sep 24, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MA
    Mancini AnthonySee Remarks
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M$105K
    3,121 sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    23
    MA
    Mancini AnthonySee Remarks
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$626K
    3,121 sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    0
    MA
    Mancini AnthonySee Remarks
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,121 sh
    		Sep 25, 2026Sep 28, 2026
    traded Sep 25, 2026
    		+3dSEC FORM 4

    Evidence

    34
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$960K
    4,985 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    27
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$175K
    910 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    11
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M$5,678
    5,070 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    34
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$512K
    2,648 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    34
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$292K
    1,500 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    20
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$20K
    100 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AM
    Anderson Elizabeth MDirector
    RVMDRevolution Medicines, Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,070 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    19
    MA
    Mancini AnthonySee Remarks
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$347K
    1,764 sh
    		Sep 18, 2026Sep 22, 2026
    traded Sep 18, 2026
    		+4dSEC FORM 4

    Evidence

    26
    AJ
    Anders JackChief Financial Officer
    RVMDRevolution Medicines, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$796K
    3,992 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001969082-26-000011
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 25, 2026
    Published
    Sep 29, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    Cislini Jeff
    Role
    SVP & General Counsel
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Revolution Medicines, Inc.
    Ticker
    RVMD
    Shares
    765
    Price per share
    $207.32
    Value
    $158,600
    Execution date (reported)
    Sep 25, 2026
    Owned after transaction
    51.8K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 765
    • Price: $207.3201

    = $158,600

    What this establishes

    Cislini Jeff filed this Form 4 reporting a open-market sale of RVMD on Sep 25, 2026. It became public on Sep 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP & General Counsel
    Cislini Jeffcik:0001969082
    Issuer
    Revolution Medicines, Inc.cik:0001628171

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.